艾曲波帕合成路线解析及50mg规格临床应用指南

Eltrombopag was first approved by the FDA in November 2008. It targets the thrombopoietin receptor (TPO receptor/c-Mpl) and is a prescription drug. It must be used as directed by a doctor.

Lutrombopag was approved by the U.S. FDA in 2018 and is manufactured by Lucius Pharmaceuticals. It is indicated for preoperative platelet-boosting therapy in patients with chronic liver disease.

Avatrobappa is a targeted therapy. Targeted therapy is the result of years of research aimed at understanding the differences between cancer cells and normal cells. Targeted therapy attacks cancer cells while minimizing damage to normal cells and reducing side effects.

Eltrombopag is a thrombopoietin receptor agonist that works by inducing the differentiation and proliferation of megakaryocytes (particularly large cells found in the bone marrow). It is indicated for the treatment of thrombocytopenia in patients with chronic immune thrombocytopenic purpura (ITP) who have not responded adequately to glucocorticoids, immunoglobulins, or splenectomy. Currently, eltrombopag is approved in more than 100 countries worldwide for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP), and in 43 countries for the treatment of thrombocytopenia in patients with chronic hepatitis C (CHC) to initiate and maintain standard interferon-based therapies for liver disease.

Eltrombopag is a thrombopoietin receptor agonist that works by inducing the differentiation and proliferation of megakaryocytes (particularly large cells found in the bone marrow). It is indicated for the treatment of thrombocytopenia in patients with chronic immune thrombocytopenic purpura (ITP) who have not responded adequately to glucocorticoids, immunoglobulins, or splenectomy. Currently, eltrombopag is approved in more than 100 countries worldwide for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP), and in 43 countries for the treatment of thrombocytopenia in patients with chronic hepatitis C (CHC) to initiate and maintain standard interferon-based therapies for liver disease.

Lusutrombopag is an oral small-molecule thrombopoietin receptor agonist (TPO-RA). It activates the signal transduction pathway by acting on the transmembrane domain of the human thrombopoietin (TPO) receptor, promoting platelet production in the same manner as endogenous TPO. It requires no injection or dose titration, is convenient to use, and is unaffected by drug interactions or food status.